CAS 320367-13-3

Lixisenatida

Descripción:

Lixisenatida es un péptido sintético que pertenece a la clase de agonistas del receptor del péptido 1 similar al glucagón (GLP-1), utilizado principalmente en el manejo de la diabetes mellitus tipo 2. Se caracteriza por su capacidad para aumentar la secreción de insulina en respuesta a niveles elevados de glucosa en sangre, ayudando así en el control glucémico. Lixisenatida es una versión modificada del GLP-1 que ocurre de forma natural, con alteraciones estructurales que mejoran su estabilidad y prolongan su acción en el cuerpo. La sustancia se administra mediante inyección subcutánea y tiene una vida media relativamente corta en comparación con otros agonistas del GLP-1, lo que requiere una dosificación una vez al día. Sus efectos farmacológicos incluyen promover la saciedad, reducir el apetito y ralentizar el vaciamiento gástrico, lo que contribuye al manejo del peso en pacientes diabéticos. Además, se ha estudiado Lixisenatida por sus beneficios cardiovasculares, aunque su función principal sigue siendo la regulación de la glucosa. Al igual que con otros medicamentos de su clase, los efectos secundarios potenciales pueden incluir trastornos gastrointestinales, como náuseas y vómitos, así como un riesgo de pancreatitis.

Fórmula: C₂₁₅H₃₄₇N₆₁O₆₅S

Lixisenatide

CAS: 320367-13-3

Lixisenatide is an exenatide-related GLP-1 agonist injected once daily for glycemic control in adult diabetes II. In myocardial ischemia-reperfusion injury studies with rats, a cardioprotective activity could be shown. Furthermore, administration of lixisenatide rescued spatial memory and synaptic plasticity from amyloid β-protein-induced impairments. Bachem provides this product solely for uses within the scope of any statute or law providing for an immunity, exemption, or exception to patent infringement (“Exempted Uses”), including but not limited to 35 U.S.C. § 271(e)(1) in the United States, the Bolar type exemption in Europe, and any corresponding exception to patent infringement in any other country. It is the sole responsibility of the purchaser or user of this product, and the purchaser or user of this product agrees to engage only in such Exempted Uses, and to comply with all applicable intellectual property laws and/or regulations. The purchaser of this product agrees to indemnify Bachem against all claims in connection with the performance of the respective commercial agreement (e.g. supply agreement) and possible infringements of intellectual property rights.

Fórmula: C₂₁₅H₃₄₇N₆₁O₆₅S

Pureza: 97.2%

Forma y color: White Lyophilisate

Peso molecular: 4858.56

Ref: 01-4084106

Lixisenatide

CAS: 320367-13-3

Fórmula: C₂₁₅H₃₄₇N₆₁O₆₅S

Pureza: %

Peso molecular: 4858.4904

Ref: IN-DA00C6LD

Lixisenatide

CAS: 320367-13-3

Lixisenatide: Injectable GLP-1 agonist for T2DM, controls blood sugar.

Fórmula: C₂₁₅H₃₄₇N₆₁O₆₅S

Forma y color: Solid

Peso molecular: 4858.49

Ref: TM-TP1340

Lixisenatide

CAS: 320367-13-3

Fórmula: C₂₁₅H₃₄₇N₆₁O₆₅S

Pureza: 95%~99%

Forma y color: White to Off-white Powder

Peso molecular: 4858.55

Ref: BP-BPPG047

Lixisenatide

CAS: 320367-13-3

Lixisenatide is a peptide hormone that belongs to the class of dipeptidyl peptidase-4 inhibitors. It is used in the treatment of type 2 diabetes, including those with a body mass index (BMI) greater than 27 kg/m2 or who have had type 2 diabetes for more than 10 years. Lixisenatide reduces postprandial blood glucose levels by delaying gastric emptying and increasing glucagon-like peptide-1 (GLP-1) release. Lixisenatide has been shown to be effective in reducing cardiovascular events in people with congestive heart failure. Lixisenatide also has water vapor and cardiac effects that are similar to those of GLP-1 agonists.

Fórmula: C₂₁₅H₃₄₇N₆₁O₆₅S

Pureza: Min. 95%

Peso molecular: 4,858.6 g/mol

Ref: 3D-LIX-3799-PI

Lixisenatide

CAS: 320367-13-3

Custom research peptide; min purity 95%. For different specs please use the Peptide Quote Tool

Fórmula: C₂₁₅H₃₄₇N₆₁O₆₅S

Peso molecular: 4,858.49 g/mol

Ref: 3D-PP50581